DC Field | Value | Language |
---|---|---|
dc.contributor.author | Y G Na | - |
dc.contributor.author | H S Jun | - |
dc.contributor.author | D Kim | - |
dc.contributor.author | Byoung Chul Park | - |
dc.contributor.author | S K Lim | - |
dc.contributor.author | K H Lee | - |
dc.contributor.author | S J Hwang | - |
dc.contributor.author | J S Park | - |
dc.contributor.author | S H Jung | - |
dc.contributor.author | C W Cho | - |
dc.date.accessioned | 2017-04-19T10:30:11Z | - |
dc.date.available | 2017-04-19T10:30:11Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0253-2964 | - |
dc.identifier.uri | 10.1002/bkcs.10861 | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/13551 | - |
dc.description.abstract | In order to improve water solubility of a lipophilic drug, tacrolimus (FK506), two prodrugs (FK506-G or FK506-S) such as FK506-M32-LS-G (FK506-G) and FK506-M32-LS-SL (FK506-S) were synthesized. Two prodrugs (FK506-G or FK506-S), including FK506, were characterized by differential scanning calorimetry (DSC), X-ray diffractometry (XRD), scanning electron microscopy (SEM), enzymatic kinetics, and cytotoxicity. A phase solubility test was conducted in distilled water, and the solubility of two prodrugs (FK506-G or FK506-S) was measured in various pH values for pH solubility profiles. Most interesting was that FK506-S showed the highest solubility, 866 μg/mL in water. In vitro enzymatic kinetics of two prodrugs (FK506-G or FK506-S) in human plasma was evaluated by measuring the decrease of FK506-G or FK506-S as well as the increase of FK506 by HPLC, and FK506-G or FK506-S was metabolized in 1 h in human plasma. Two prodrugs (FK506-G or FK506-S) including FK506 showed an IC50 of 336.6 μg/mL for FK506, 337.9 μg/mL for FK506-G, or 480.1 μg/mL for FK506-S against a conjunctive cell line, Clone 1-5c-4 cells. Taken together, FK506-S could be the most optimal prodrug for aqueous preparations based on preformulation data. | - |
dc.publisher | Wiley | - |
dc.title | Preformulation of FK506 prodrugs for improving solubility = FK506 프로드럭의 용해도를 개선한 제형 | - |
dc.title.alternative | Preformulation of FK506 prodrugs for improving solubility | - |
dc.type | Article | - |
dc.citation.title | Bulletin of Korean Chemical Society | - |
dc.citation.number | 0 | - |
dc.citation.endPage | 1319 | - |
dc.citation.startPage | 1313 | - |
dc.citation.volume | 37 | - |
dc.contributor.affiliatedAuthor | Byoung Chul Park | - |
dc.contributor.alternativeName | 나영국 | - |
dc.contributor.alternativeName | 전혜석 | - |
dc.contributor.alternativeName | 김대희 | - |
dc.contributor.alternativeName | 박병철 | - |
dc.contributor.alternativeName | 임시규 | - |
dc.contributor.alternativeName | 이기호 | - |
dc.contributor.alternativeName | 황성주 | - |
dc.contributor.alternativeName | 박정숙 | - |
dc.contributor.alternativeName | 정상훈 | - |
dc.contributor.alternativeName | 조청원 | - |
dc.identifier.bibliographicCitation | Bulletin of Korean Chemical Society, vol. 37, pp. 1313-1319 | - |
dc.identifier.doi | 10.1002/bkcs.10861 | - |
dc.subject.keyword | Cytotoxicity | - |
dc.subject.keyword | FK506 | - |
dc.subject.keyword | Preformulation | - |
dc.subject.keyword | Prodrug | - |
dc.subject.keyword | Solubility | - |
dc.subject.local | Cytotoxicity | - |
dc.subject.local | cytotoxicity | - |
dc.subject.local | FK506 | - |
dc.subject.local | Preformulation | - |
dc.subject.local | Prodrug | - |
dc.subject.local | Solubility | - |
dc.subject.local | solubility | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.